Advertisements



We are Sorry, This Page doesn't Exist


Alnylam Falls on Pfizer"s Rare Disease Drug Success

Shares of Alnylam (ALNY) fall by more than 8% after Pfizer reports top-line results from the phase III study of tafam.....»»

Category: topSource: zacksApr 2nd, 2018

Lilly"s Taltz Positive in Phase III Label Expansion Study

Lilly's (LLY) psoriasis drug, Taltz, meets all endpoints in a phase III study evaluating it in patients with ankylosing spondylitis. .....»»

Category: smallbizSource: nytFeb 14th, 2018

BioLineRx Cancer Drug Positive as Monotherapy in Phase IIa

BioLineRx (BLRX) posts encouraging partial results from the monotherapy portion of a phase IIa COMBAT study, assessing its lead pipeline candidate, BL-8040, for pancreatic cancer p.....»»

Category: smallbizSource: nytJan 18th, 2018

Novartis Announces Positive Data on Sickle Cell Disease Drug

Novartis (NVS) announced positive data from a phase II study, SUSTAIN, on pipeline candidate crizanlizumab which deferred the time to first s.....»»

Category: worldSource: nytDec 12th, 2017

Bristol-Myers (BMY) Reports Positive Data on Leukemia Drug

Bristol-Myers Squibb Company (BMY) announced positive data from an ongoing phase II study on leukemia drug Sprycel in addition to a chemotherapy regimen modelled on a Berlin-Frankfurt-Munster high-risk backbone for two years. .....»»

Category: worldSource: nytDec 12th, 2017

Zogenix (ZGNX) Stock Skyrocketed Over 170% Today: Here"s Why

On Friday, shares of pharmaceutical company Zogenix Inc. (ZGNX) are skyrocketing after it announced positive results from its first Phase 3 study of ZX008, a drug used to treat the rare epilepsy form Dravet Syndrome. On Friday, sha.....»»

Category: worldSource: nytSep 29th, 2017

Roche (RHHBY) Announces Positive Data on Leukemia Drug

Roche Holdings AG (RHHBY) announced positive results from the phase III study, MURANO on leukemia drug Venclexta. Roche Holdings AG RHHBY announced positive results from the phase III study, MURANO.The study evaluated Vencle.....»»

Category: personnelSource: nytSep 19th, 2017

Novartis Announces Positive Data on Urticaria Drug Xolair

Novartis AG (NVS) announced new positive data on chronic spontaneous urticaria (CSU) drug Xolair from a phase IIIb study, OPTIMA. .....»»

Category: smallbizSource: nytSep 18th, 2017

Alnylam Pharmaceuticals (ALNY) & Sanofi Genzyme Report Positive Results from Ongoing Phase 2 Open-Label Extension Study - Presentation

Alnylam Pharmaceuticals (ALNY) & Sanofi Genzyme Report Positive Results from Ongoing Phase 2 Open-Label Extension Study - Presentation.....»»

Category: topSource: seekingalphaJul 11th, 2017

Arena Pharmaceuticals stock skyrockets on positive hypertension-drug study

Arena Pharmaceuticals Inc. shares jumped 35% in late trading Monday after the company announced positive results from a drug study. The San Diego company said that a phase 2 study of a drug targeted at pulmonary arterial hyperte.....»»

Category: topSource: marketwatchJul 10th, 2017

Catalyst Enrolls First Patient in Phase III Firdapse Study

Catalyst (CPRX) enrolls the first patient in its phase III clinical trial (MSK-002) to evaluate the efficacy and safety of Firdapse in patients with MuSK antibody positive Myasthenia Gravis. Catalyst Pharmaceuticals, Inc. CPRX, enroled.....»»

Category: worldSource: nytApr 20th, 2018

Alnylam (ALNY) Reports Positive Data for RNAi Candidate

Alnylam (ALNY) announced encouraging results from phase I and phase I/II open-label extension studies of givosiran, which is being evaluated for the treatment of a.....»»

Category: worldSource: nytApr 17th, 2018

Therapix Biosciences up 36% after positive results from Phase 2 THX-110 study

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 9th, 2018

Merck"s stock surges after positive Keytruda trial results

Shares of Merck & Co. Inc. surged 2.6% in premarket trade Monday, after the drug maker said its cancer treatment Keytruda met the primary endpoint of a phase 3 trial evaluating the Keytr.....»»

Category: topSource: marketwatchApr 9th, 2018

AbbVie shares jump 2.2% on news of positive results in rheumatoid arthritis drug trial

Shares of AbbVie Inc. jumped 2.2% in premarket trade Monday, after the company reported positive results in a late-stage trial of a treatment for rheumatoid arthritis. AbbVie said the phase 3 trial of upadacitinib met its primary endpoints. Upadaciti.....»»

Category: topSource: marketwatchApr 9th, 2018

Altimmune announces "positive" data from Phase 2a study of NasoVax

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMar 27th, 2018

Arena Pharmaceuticals" stock rockets after positive drug trial results

Shares of Arena Pharmaceuticals Inc. shot up 34% in premarket trade Tuesday, after the drugmaker reported positive results from a phase 2 trial of its treatment for ulcerative colitis. The rally comes a.....»»

Category: topSource: marketwatchMar 20th, 2018

Arbutus Announces Corporate Update and Year-End 2017 Financial Results

ARB-1467 Phase II Combination Study Beginning in 1Q18Two New Drug C.....»»

Category: earningsSource: benzingaMar 14th, 2018

Alnylam to present new data on APOLLO Phase 3 study and ALN-TTRsc02

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMar 14th, 2018

Study: Cholesterol drug lowers risk of death, heart attack

Heart attack survivors who can't tolerate or get enough help from cholesterol-lowering drugs called statins soon may have an easier time getting insurers to pay for a newer medicine that works in a different way......»»

Category: topSource: foxnewsMar 10th, 2018